Aura Biosciences (AURA) Operating Income (2020 - 2026)

Aura Biosciences has reported Operating Income for 7 years, with the latest figure at -$34.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 20.08% year-over-year to -$34.9 million; the trailing twelve-month figure through Mar 2026 stood at -$28.1 million (down 12.67% YoY), and the FY2025 full-year result was -$22.3 million, down 22.21% from the prior year.
• Operating Income for Q1 2026 stood at -$34.9 million, down from $63.3 million in the prior quarter.
• The five-year high for Operating Income was $63.3 million in Q4 2025, with the low at -$34.9 million in Q1 2026.
• Historically, Operating Income has averaged -$13.0 million across 5 years, with a median of -$20.5 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Income plunged 116.15% — and 2024, when it surged 302.07%.
• Aura Biosciences' Operating Income stood at -$17.6 million in 2022, then plunged by 40.71% to -$24.8 million in 2023, then jumped by 302.07% to $50.1 million in 2024, then grew by 26.35% to $63.3 million in 2025, then slumped by 155.1% to -$34.9 million in 2026.
• The last three Operating Income figures came in at -$34.9 million (Q1 2026), $63.3 million (Q4 2025), and -$27.9 million (Q3 2025), per Business Quant data.